Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 127 (1) , 161-166.e1
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthmaJournal of Allergy and Clinical Immunology, 2009
- Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthmaCurrent Medical Research and Opinion, 2007
- Cost‐effectiveness of asthma control: an economic appraisal of the GOAL studyAllergy, 2006
- Cost‐effectiveness of early intervention with once‐daily budesonide in children with mild persistent asthma: results from the START studyPediatric Allergy and Immunology, 2006
- Cost‐effectiveness of current and optimal treatment for adult asthmaInternal Medicine Journal, 2006
- Single-Inhaler Combination Therapy for AsthmaPharmacoEconomics, 2006
- Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curvesAnnals of Allergy, Asthma & Immunology, 2005
- Country-specific cost-effectiveness of early intervention with budesonide in mild asthmaEuropean Respiratory Journal, 2004
- Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthmaJournal of Allergy and Clinical Immunology, 2003
- Estimating the cost of illness.American Journal of Public Health and the Nations Health, 1967